The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been considered a promising anticancer agent, because it selectively induces apoptotic cell death in cancer cells, but not in normal cells [1,2,3,4]. The gene discussed is TNFSF10; the disease is cancer.